| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2011151358 |
| Title |
2 -Amino- Pyrimidine Derivatives Useful As Inhibitors of Jnk. |
| Abstract |
Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0J8PJ |
Drug Info
|
IC50 = 46 nM |
Click to Show More |
[1] |
|
2
|
D0CS9R
|
Drug Info
|
IC50 = 71 nM
|
[1] |
| Patent ID |
WO2011151357 |
| Title |
Inhibitors of Jnk. |
| Abstract |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: wherein m, n, p, q, X Y, Z, A, R1, R2, R3, R4, R5 and Y6 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D01FTR |
Drug Info
|
IC50 = 31 nM |
Click to Show More |
[1] |
|
2
|
D0QK6D
|
Drug Info
|
IC50 = 135 nM
|
[1] |
| Patent ID |
WO2012083092 |
| Title |
Bi-Dentate Compounds As Kinase Inhibitors. |
| Abstract |
The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide rnimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38. |
| Applicant(s) |
Sanford-Burnham Medical Research Institute |
| Representative Drug(s) |
D08OJQ |
Drug Info
|
IC50 = 0.3 nM |
Click to Show More |
[1] |
|
2
|
D0G7LB
|
Drug Info
|
IC50 = 18 nM
|
[1] |
|
3
|
D09EWC
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2013074986 |
| Title |
Inhibitors of C-Jun-N-Terminal Kinase (Jnk). |
| Abstract |
The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases. |
| Applicant(s) |
Dana-Farber Cancer Institute, Inc |
| Representative Drug(s) |
D04JVY |
Drug Info
|
IC50 = nM range |
Click to Show More |
[1] |
|
2
|
D0PG5N
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
WO2014170706 |
| Title |
Galloyl Benzamide-Based Compounds As Jnk Modulators. |
| Abstract |
The present invention relates to the use of compounds having a galloyl benzamide structure in the treatment and/or prevention of medical conditions mediated through c-Jun N-terminal kinases (JNKs) and to pharmaceutical compositions comprising said compounds. |
| Applicant(s) |
Universit Degli Studi Di Bari |
| Representative Drug(s) |
D0O2EF |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2010091310 |
| Title |
Inhibitors of Jun N-Terminal Kinase. |
| Abstract |
The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease. |
| Applicant(s) |
Elan Pharmaceuticals, Inc |
| Representative Drug(s) |
D0GX7W |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011071491 |
| Title |
Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol. |
| Abstract |
Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided. |
| Applicant(s) |
Signal Pharmaceuticals |
| Patent ID |
WO2010108155 |
| Title |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator. |
| Abstract |
This invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH. |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
